Jason Kantor

Credit Suisse Sees Solid Q4 Earnings For Kite Pharma

Credit Suisse Sees All Eyes On Eyeguard B Data for XOMA

Credit Suisse Reiterates Neutral, Raises PT On Pharmacyclics As Deal Looks Likely To Happen

Credit Suisse Sees All Eyes On Eyeguard B Data for XOMA

Credit Suisse Reiterates Neutral, Raises PT On Pharmacyclics As Deal Looks Likely To Happen

Credit Suisse Downgrades Pharmacyclics Amid Takeover Rumors

UPDATE: Credit Suisse Raises Price Target On Kite Pharma On AMGN Deal

Credit Suisse Downgrades Pharmacyclics Amid Takeover Rumors

UPDATE: Credit Suisse Raises Price Target On Kite Pharma On AMGN Deal

UPDATE: Credit Suisse Raises PT On Kite Pharma On Strong Outlook For CAR-T

UPDATE: Credit Suisse Downgrades Ariad Pharmaceuticals As Launch Metrics Are Still Weak

Jason Kantor Recent News

The Medicines Company Surges Amid Credit Suisse Upgrade

UPDATE: Credit Suisse Downgrades Cubist Pharmaceuticals On Execution Risk To Global Expansion Of Hospital Franchise

XOMA Corp Volatile Amid Differing Analyst Reports

Credit Suisse Expects New Pricing To Boost Sales For Ariad Pharmaceuticals

UPDATE: Credit Suisse Reiterates On Esperion Therapeutics Inc On Multiple Positive Factors

Credit Suisse Sees Continued Operational Progress For Kite Pharma

UPDATE: Credit Suisse Reiterates On BIND Therapeutics After AMGN Declines Option On Accurin Technology

Credit Suisse Raises Q2 Imbruvica Sales Forecast For Pharmacyclics

UPDATE: Credit Suisse Initiates On Alder Biopharmaceuticals, Optimistic On 'Derisked' Assets

UPDATE: Credit Suisse Downgrades The Medicines Company Following Negative Cangrelor Panel

Credit Suisse Reports Ariad's Iclusig is 'Essential Drug'

Credit Suisse Maintains on Cubist Pharmaceuticals

UPDATE: Credit Suisse Raises PT on Ariad Pharmaceuticals, View Remains Cautious

UPDATE: Credit Suisse Reiterates on Ariad Pharmaceuticals as Iclusig Re-Launch is Expected to be Bumpy

UPDATE: Credit Suisse Raises PT on Prothena Following Deal with Roche

UPDATE: Credit Suisse Downgrades Infinity Pharmaceuticals on Limited Clinical News in 2014

UPDATE: Credit Suisse Initiates PTC Therapeutics at Outperform on Bullish Thesis

UPDATE: Credit Suisse Downgrades Spectrum Pharmaceuticals on Limited Growth Opportunities and Increased Risk

UPDATE: Credit Suisse Initiates Portola Pharmaceuticals at Outperform Rating Ahead of PIII APEX Trial